Back
POT1HGNC medRxivPenetrance updatePhenotypic expansion

Cancer risk and survival outcomes in germline POT1 variant carriers

Raper AC, Schultz BI, Kim J, et al. — medRxiv 2026 · November 2026
Relevance score
7/10
Disease / domain
Hereditary cancer predisposition (POT1)
Source
medRxiv
DOI 10.64898/2026.11.10.26367070

Gene / mechanism

POT1

Germline pathogenic or likely pathogenic POT1 variants, and functionally assessed variants

Summary

The prevalence of germline POT1 variants, the associated tumour spectrum, cancer risk and survival outcomes were incompletely described, and clinical management guidelines vary. The authors studied carriers of pathogenic, likely pathogenic or functionally assessed variants in three biobanks (Penn Medicine Biobank, n = 51,172; Geisinger MyCode, n = 220,582; UK Biobank, n = 469,558) and a Penn Medicine clinical cohort. Estimated POT1 variant prevalence ranged from 1:1,279 to 1:2,902, and cancer diagnoses were more frequent in carriers than in non-carriers in all three biobanks (OR 3.41, 2.23 and 1.40). Cancer incidence increased from the mid-30s, without evidence of increased mortality, and lung cancer was associated with carrier status in two biobanks. The authors conclude that POT1 confers a moderately increased cancer risk (1.5- to 3.5-fold) with a broad tumour spectrum.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

Analysis

The genotype-first biobank approach limits the ascertainment bias of family-based series and yields a moderate risk (1.5- to 3.5-fold). The lung cancer association and the absence of excess mortality await confirmation after peer review, especially as the carrier definition includes variants retained on functional data. For genetic counselling, these figures argue for surveillance proportionate to the risk rather than modelled on high-penetrance syndromes.

Analysis by Dr Thibaut Benquey

Why this score?

Impact 2/3Evidence 3/3Novelty 1/2Sample 1/1Publication 0/1

Clinical impact: 2/3 · Evidence strength: 3/3 · Novelty: 1/2 · Sample size: 1/1 · Publication status: 0/1 → Total: 7/10

Keywords

POT1penetrancebiobanklung cancergermline predisposition

More articles on POT1

Weekly report in your inbox

Every Wednesday · Annotated selection · Free · Unsubscribe anytime